New York, December 19, 2024 – According to a research report by Lighthouse Equity Research, SBC Medical Group Holdings, a leader in aesthetic medicine with a stronghold in Japan, is accelerating its global expansion strategy. The company, which operates 224 clinics worldwide, including 164 franchisee locations, reported $193 million in revenue in 2023, driven by $1.1 billion in retail sales from its network. With a five-year revenue CAGR of 24%, SBC is poised for continued growth, projecting a 25% revenue increase in 2025.
Recent milestones include the acquisition of Singapore-based Aesthetic Healthcare Holdings in November 2024, positioning Singapore as its Asian operations hub. SBC is also expanding in high-growth markets like Vietnam and Irvine, California. As non-invasive procedures dominate the $245 billion global medical aesthetics market, SBC leverages this trend to bolster recurring revenues. The company’s strong financial position, with $137 million in cash and low debt, supports its ambitious expansion.
SBC aims to capitalize on untapped markets, including Japan’s 10% market penetration for aesthetic medicine and increasing demand among men. Its innovative franchise model and advanced technologies place it at the forefront of the aesthetic medical industry’s rapid evolution. The company’s target price stands at $6.57, reflecting its robust growth potential and market leadership.
